Site-Specific Considerations on Engineered T Cells for Malignant Gliomas

Immunotherapy has revolutionized cancer treatment. Despite the recent advances in immunotherapeutic approaches for several tumor entities, limited response has been observed in malignant gliomas, including glioblastoma (GBM). Conversely, one of the emerging immunotherapeutic modalities is chimeric a...

Descripción completa

Detalles Bibliográficos
Autores principales: Elmadany, Nirmeen, Alhalabi, Obada T., Platten, Michael, Bunse, Lukas
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2022
Materias:
Review
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9312945/
https://www.ncbi.nlm.nih.gov/pubmed/35885047
http://dx.doi.org/10.3390/biomedicines10071738

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9312945/
https://www.ncbi.nlm.nih.gov/pubmed/35885047
http://dx.doi.org/10.3390/biomedicines10071738

Ejemplares similares